Timothy P Hughes

List of Publications by Citations

405 papers	33,485 citations	72 h-index	180 g-index
419 ext. papers	37,457 ext. citations	5.6 avg, IF	6.55 L-index

#	Paper	IF	Citations
405	Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. *New England Journal of Medicine*, **2006**, 355, 2408-17	59.2	2811
404	Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. *New England Journal of Medicine*, **2003**, 348, 994-1004	59.2	2797
403	European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. *Blood*, **2013**, 122, 872-84	2.2	1413
402	Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. *New England Journal of Medicine*, **2010**, 362, 2251-9	59.2	1266
401	Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet. *Journal of Clinical Oncology*, **2009**, 27, 6041-51	2.2	1019
400	Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. *Blood*, **2006**, 108, 1809-20	2.2	998
399	Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results. *Blood*, **2006**, 108, 28-37	2.2	977
398	Targetable kinase-activating lesions in Ph-like acute lymphoblastic leukemia. *New England Journal of Medicine*, **2014**, 371, 1005-15	59.2	885
397	BCR-ABL1 lymphoblastic leukaemia is characterized by the deletion of Ikaros. *Nature*, **2008**, 453, 110-4	50.4	835
396	A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias. *New England Journal of Medicine*, **2013**, 369, 1783-96	59.2	736
395	Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia. *Leukemia*, **2009**, 23, 1054-61	10.7	711
394	Dynamics of chronic myeloid leukaemia. *Nature*, **2005**, 435, 1267-70	50.4	667
393	Lin28 promotes transformation and is associated with advanced human malignancies. *Nature Genetics*, **2009**, 41, 843-8	36.3	641
392	Long-Term Outcomes of Imatinib Treatment for Chronic Myeloid Leukemia. *New England Journal of Medicine*, **2017**, 376, 917-927	59.2	618
391	High frequency of point mutations clustered within the adenosine triphosphate-binding region of BCR/ABL in patients with chronic myeloid leukemia or Ph-positive acute lymphoblastic leukemia who develop imatinib (STI571) resistance. *Blood*, **2002**, 99, 3472-5	2.2	582
390	Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study. *Blood*, **2013**, 122, 515-22	2.2	519
389	Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapy. *Blood*, **2007**, 109, 2303-9	2.2	498

388	Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial. *Leukemia*, **2016**, 30, 1044-54	10.7	497
387	Intermittent target inhibition with dasatinib 100 mg once daily preserves efficacy and improves tolerability in imatinib-resistant and -intolerant chronic-phase chronic myeloid leukemia. *Journal of Clinical Oncology*, **2008**, 26, 3204-12	2.2	408
386	Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trial. *Lancet Oncology, The*, **2011**, 12, 841-51	21.7	383
385	Long-term prognostic significance of early molecular response to imatinib in newly diagnosed chronic myeloid leukemia: an analysis from the International Randomized Study of Interferon and STI571 (IRIS). *Blood*, **2010**, 116, 3758-65	2.2	382
384	OCT-1-mediated influx is a key determinant of the intracellular uptake of imatinib but not nilotinib (AMN107): reduced OCT-1 activity is the cause of low in vitro sensitivity to imatinib. *Blood*, **2006**, 108, 697-704	2.2	370
383	Nilotinib vs imatinib in patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: ENESTnd 3-year follow-up. *Leukemia*, **2012**, 26, 2197-203	10.7	335
382	Early molecular and cytogenetic response is predictive for long-term progression-free and overall survival in chronic myeloid leukemia (CML). *Leukemia*, **2012**, 26, 2096-102	10.7	328
381	Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia after failure of first-line imatinib: a randomized phase 2 trial. *Blood*, **2007**, 109, 5143-50	2.2	320
380	Sequential ABL kinase inhibitor therapy selects for compound drug-resistant BCR-ABL mutations with altered oncogenic potency. *Journal of Clinical Investigation*, **2007**, 117, 2562-9	15.9	315
379	Dasatinib induces durable cytogenetic responses in patients with chronic myelogenous leukemia in chronic phase with resistance or intolerance to imatinib. *Leukemia*, **2008**, 22, 1200-6	10.7	311
378	Desirable performance characteristics for BCR-ABL measurement on an international reporting scale to allow consistent interpretation of individual patient response and comparison of response rates between clinical trials. *Blood*, **2008**, 112, 3330-8	2.2	306
377	Nilotinib is effective in patients with chronic myeloid leukemia in chronic phase after imatinib resistance or intolerance: 24-month follow-up results. *Blood*, **2011**, 117, 1141-5	2.2	296
376	Most CML patients who have a suboptimal response to imatinib have low OCT-1 activity: higher doses of imatinib may overcome the negative impact of low OCT-1 activity. *Blood*, **2007**, 110, 4064-72	2.2	277
375	The allosteric inhibitor ABL001 enables dual targeting of BCR-ABL1. *Nature*, **2017**, 543, 733-737	50.4	256
374	Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is active in patients with imatinib-resistant or -intolerant accelerated-phase chronic myelogenous leukemia. *Blood*, **2008**, 111, 1834-9	2.2	255
373	International Randomized Study of Interferon Vs STI571 (IRIS) 8-Year Follow up: Sustained Survival and Low Risk for Progression or Events in Patients with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Treated with Imatinib.. *Blood*, **2009**, 114, 1126-1126	2.2	252
372	Impact of baseline BCR-ABL mutations on response to nilotinib in patients with chronic myeloid leukemia in chronic phase. *Journal of Clinical Oncology*, **2009**, 27, 4204-10	2.2	248
371	Macrophage colony-stimulating factor receptor c-fms is a novel target of imatinib. *Blood*, **2005**, 105, 3127-32	7.3	244

370	Phase III, randomized, open-label study of daily imatinib mesylate 400 mg versus 800 mg in patients with newly diagnosed, previously untreated chronic myeloid leukemia in chronic phase using molecular end points: tyrosine kinase inhibitor optimization and selectivity study. *Journal of Clinical Oncology*, **2010**, 28, 424-30	2.2	235
369	Dasatinib treatment of chronic-phase chronic myeloid leukemia: analysis of responses according to preexisting BCR-ABL mutations. *Blood*, **2009**, 114, 4944-53	2.2	230
368	Moving treatment-free remission into mainstream clinical practice in CML. *Blood*, **2016**, 128, 17-23	2.2	224
367	Patients with chronic myeloid leukemia who maintain a complete molecular response after stopping imatinib treatment have evidence of persistent leukemia by DNA PCR. *Leukemia*, **2010**, 24, 1719-24	10.7	222
366	Ponatinib efficacy and safety in Philadelphia chromosome-positive leukemia: final 5-year results of the phase 2 PACE trial. *Blood*, **2018**, 132, 393-404	2.2	221
365	Early molecular response predicts outcomes in patients with chronic myeloid leukemia in chronic phase treated with frontline nilotinib or imatinib. *Blood*, **2014**, 123, 1353-60	2.2	196
364	Nilotinib in imatinib-resistant or imatinib-intolerant patients with chronic myeloid leukemia in chronic phase: 48-month follow-up results of a phase II study. *Leukemia*, **2013**, 27, 107-12	10.7	169
363	Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia resistant to imatinib at a dose of 400 to 600 milligrams daily: two-year follow-up of a randomized phase 2 study (START-R). *Cancer*, **2009**, 115, 4136-47	6.4	168
362	Ponatinib versus imatinib for newly diagnosed chronic myeloid leukaemia: an international, randomised, open-label, phase 3 trial. *Lancet Oncology, The*, **2016**, 17, 612-21	21.7	164
361	Dasatinib cellular uptake and efflux in chronic myeloid leukemia cells: therapeutic implications. *Clinical Cancer Research*, **2008**, 14, 3881-8	12.9	157
360	Dasatinib in the treatment of chronic myeloid leukemia in accelerated phase after imatinib failure: the START a trial. *Journal of Clinical Oncology*, **2009**, 27, 3472-9	2.2	154
359	Functional activity of the OCT-1 protein is predictive of long-term outcome in patients with chronic-phase chronic myeloid leukemia treated with imatinib. *Journal of Clinical Oncology*, **2010**, 28, 2761-7	2.2	153
358	Impact of early dose intensity on cytogenetic and molecular responses in chronic- phase CML patients receiving 600 mg/day of imatinib as initial therapy. *Blood*, **2008**, 112, 3965-73	2.2	151
357	Prognosis for patients with CML and >10% BCR-ABL1 after 3 months of imatinib depends on the rate of BCR-ABL1 decline. *Blood*, **2014**, 124, 511-8	2.2	145
356	Selecting optimal second-line tyrosine kinase inhibitor therapy for chronic myeloid leukemia patients after imatinib failure: does the BCR-ABL mutation status really matter?. *Blood*, **2009**, 114, 5426-35	2.2	141
355	Long-term imatinib therapy promotes bone formation in CML patients. *Blood*, **2008**, 111, 2538-47	2.2	136
354	Minimal residual disease after allogeneic bone marrow transplantation for chronic myeloid leukaemia in first chronic phase: correlations with acute graft-versus-host disease and relapse. *British Journal of Haematology*, **1993**, 84, 67-74	4.5	134
353	Early molecular response and female sex strongly predict stable undetectable BCR-ABL1, the criteria for imatinib discontinuation in patients with CML. *Blood*, **2013**, 121, 3818-24	2.2	123

352	Persistent activation of nuclear factor-kappaB in cultured rat hepatic stellate cells involves the induction of potentially novel Rel-like factors and prolonged changes in the expression of IkappaB family proteins. *Hepatology*, **1999**, 30, 761-9	11.2	122
351	In vitro sensitivity to imatinib-induced inhibition of ABL kinase activity is predictive of molecular response in patients with de novo CML. *Blood*, **2005**, 106, 2520-6	2.2	121
350	Establishment of the first World Health Organization International Genetic Reference Panel for quantitation of BCR-ABL mRNA. *Blood*, **2010**, 116, e111-7	2.2	120
349	BCR-ABL messenger RNA levels continue to decline in patients with chronic phase chronic myeloid leukemia treated with imatinib for more than 5 years and approximately half of all first-line treated patients have stable undetectable BCR-ABL using strict sensitivity criteria. *Clinical Cancer Research*, **2007**, 13, 7080-5	12.9	116
348	Molecular monitoring of BCR-ABL as a guide to clinical management in chronic myeloid leukaemia. *Blood Reviews*, **2006**, 20, 29-41	11.1	116
347	Asciminib in Chronic Myeloid Leukemia after ABL Kinase Inhibitor Failure. *New England Journal of Medicine*, **2019**, 381, 2315-2326	59.2	114
346	Rac2-MRC-cIII-generated ROS cause genomic instability in chronic myeloid leukemia stem cells and primitive progenitors. *Blood*, **2012**, 119, 4253-63	2.2	110
345	Dysregulation of bone remodeling by imatinib mesylate. *Blood*, **2010**, 115, 766-74	2.2	108
344	CML patients with deep molecular responses to TKI have restored immune effectors and decreased PD-1 and immune suppressors. *Blood*, **2017**, 129, 1166-1176	2.2	95
343	The Src/ABL kinase inhibitor dasatinib (BMS-354825) inhibits function of normal human T-lymphocytes in vitro. *Clinical Immunology*, **2008**, 127, 330-9	9	93
342	Association between imatinib transporters and metabolizing enzymes genotype and response in newly diagnosed chronic myeloid leukemia patients receiving imatinib therapy. *Haematologica*, **2013**, 98, 193-200	6.6	83
341	Integrative genomic analysis reveals cancer-associated mutations at diagnosis of CML in patients with high-risk disease. *Blood*, **2018**, 132, 948-961	2.2	80
340	Treatment-Free Remission After Second-Line Nilotinib Treatment in Patients With Chronic Myeloid Leukemia in Chronic Phase: Results From a Single-Group, Phase 2, Open-Label Study. *Annals of Internal Medicine*, **2018**, 168, 461-470	8	78
339	Initial molecular response at 3 months may predict both response and event-free survival at 24 months in imatinib-resistant or -intolerant patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase treated with nilotinib. *Journal of Clinical Oncology*, **2012**, 30, 4323-9	2.2	78
338	Plasma exposure of imatinib and its correlation with clinical response in the Tyrosine Kinase Inhibitor Optimization and Selectivity Trial. *Haematologica*, **2012**, 97, 731-8	6.6	76
337	Deep molecular responses achieved in patients with CML-CP who are switched to nilotinib after long-term imatinib. *Blood*, **2014**, 124, 729-36	2.2	75
336	Monoclonal antibody targeting of IL-3 receptor with CSL362 effectively depletes CML progenitor and stem cells. *Blood*, **2014**, 123, 1218-28	2.2	74
335	Population pharmacokinetic and exposure-response analysis of nilotinib in patients with newly diagnosed Ph+ chronic myeloid leukemia in chronic phase. *European Journal of Clinical Pharmacology*, **2012**, 68, 723-33	2.8	74

334	Nilotinib is associated with a reduced incidence of BCR-ABL mutations vs imatinib in patients with newly diagnosed chronic myeloid leukemia in chronic phase. *Blood*, **2013**, 121, 3703-8	2.2	73
333	Imatinib as a potential antiresorptive therapy for bone disease. *Blood*, **2006**, 107, 4334-7	2.2	71
332	Front-line and salvage therapies with tyrosine kinase inhibitors and other treatments in chronic myeloid leukemia. *Journal of Clinical Oncology*, **2011**, 29, 524-31	2.2	70
331	Clinical resistance to imatinib: mechanisms and implications. *Hematology/Oncology Clinics of North America*, **2004**, 18, 641-56, ix	3.1	69
330	Dasatinib suppresses in vitro natural killer cell cytotoxicity. *Blood*, **2008**, 111, 4415-6	2.2	68
329	Sensitive detection of BCR-ABL1 mutations in patients with chronic myeloid leukemia after imatinib resistance is predictive of outcome during subsequent therapy. *Journal of Clinical Oncology*, **2011**, 29, 4250-9	2.2	67
328	TIDEL-II: first-line use of imatinib in CML with early switch to nilotinib for failure to achieve time-dependent molecular targets. *Blood*, **2015**, 125, 915-23	2.2	65
327	Compound mutations in BCR-ABL1 are not major drivers of primary or secondary resistance to ponatinib in CP-CML patients. *Blood*, **2016**, 127, 703-12	2.2	65
326	Signalling by the □ family of cytokines. *Cytokine and Growth Factor Reviews*, **2013**, 24, 189-201	17.9	62
325	Chronic myeloid leukemia: reminiscences and dreams. *Haematologica*, **2016**, 101, 541-58	6.6	61
324	Overall survival with ponatinib versus allogeneic stem cell transplantation in Philadelphia chromosome-positive leukemias with the T315I mutation. *Cancer*, **2017**, 123, 2875-2880	6.4	57
323	Chronic myeloid leukemia CD34+ cells have reduced uptake of imatinib due to low OCT-1 activity. *Leukemia*, **2010**, 24, 765-70	10.7	57
322	Poor response to second-line kinase inhibitors in chronic myeloid leukemia patients with multiple low-level mutations, irrespective of their resistance profile. *Blood*, **2012**, 119, 2234-8	2.2	55
321	Factors affecting the outcome of allogeneic bone marrow transplantation for adult patients with refractory or relapsed acute leukaemia. *British Journal of Haematology*, **1999**, 107, 409-18	4.5	55
320	Interaction of the efflux transporters ABCB1 and ABCG2 with imatinib, nilotinib, and dasatinib. *Clinical Pharmacology and Therapeutics*, **2014**, 95, 294-306	6.1	54
319	A phase 2 study of MK-0457 in patients with BCR-ABL T315I mutant chronic myelogenous leukemia and philadelphia chromosome-positive acute lymphoblastic leukemia. *Blood Cancer Journal*, **2014**, 4, e238	7	53
318	Measurement of in vivo BCR-ABL kinase inhibition to monitor imatinib-induced target blockade and predict response in chronic myeloid leukemia. *Journal of Clinical Oncology*, **2007**, 25, 4445-51	2.2	53
317	Dynamics of chronic myeloid leukemia response to long-term targeted therapy reveal treatment effects on leukemic stem cells. *Blood*, **2011**, 118, 1622-31	2.2	52

316	Dasatinib inhibits recombinant viral antigen-specific murine CD4+ and CD8+ T-cell responses and NK-cell cytolytic activity in vitro and in vivo. *Experimental Hematology*, **2009**, 37, 256-65	3.1	51
315	Laying the foundation for genomically-based risk assessment in chronic myeloid leukemia. *Leukemia*, **2019**, 33, 1835-1850	10.7	50
314	The GM-CSF receptor family: mechanism of activation and implications for disease. *Growth Factors*, **2012**, 30, 63-75	1.6	50
313	Therapeutic concentrations of dasatinib inhibit in vitro osteoclastogenesis. *Leukemia*, **2009**, 23, 994-7	10.7	50
312	BCR-ABL1 mutation development during first-line treatment with dasatinib or imatinib for chronic myeloid leukemia in chronic phase. *Leukemia*, **2015**, 29, 1832-8	10.7	49
311	Chronic phase chronic myeloid leukemia patients with low OCT-1 activity randomized to high-dose imatinib achieve better responses and have lower failure rates than those randomized to standard-dose imatinib. *Haematologica*, **2012**, 97, 907-14	6.6	48
310	Tyrosine kinase inhibitor resistance in chronic myeloid leukemia cell lines: investigating resistance pathways. *Leukemia and Lymphoma*, **2011**, 52, 2139-47	1.9	48
309	Monitoring disease response to tyrosine kinase inhibitor therapy in CML. *Hematology American Society of Hematology Education Program*, **2009**, 477-87	3.1	48
308	The impact of multiple low-level BCR-ABL1 mutations on response to ponatinib. *Blood*, **2016**, 127, 1870-80	10	45
307	Blocking cytokine signaling along with intense Bcr-Abl kinase inhibition induces apoptosis in primary CML progenitors. *Leukemia*, **2010**, 24, 771-8	10.7	45
306	The clinical significance of ABCB1 overexpression in predicting outcome of CML patients undergoing first-line imatinib treatment. *Leukemia*, **2017**, 31, 75-82	10.7	44
305	International Randomized Study of Interferon Versus STI571 (IRIS) 7-Year Follow-up: Sustained Survival, Low Rate of Transformation and Increased Rate of Major Molecular Response (MMR) in Patients (pts) with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CMLCP) Treated with Imatinib (IM). *Blood* **2008**, 112, 186-186	2.2	44
304	Plasma adiponectin levels are markedly elevated in imatinib-treated chronic myeloid leukemia (CML) patients: a mechanism for improved insulin sensitivity in type 2 diabetic CML patients?. *Journal of Clinical Endocrinology and Metabolism*, **2010**, 95, 3763-7	5.6	43
303	OCT1 and imatinib transport in CML: is it clinically relevant?. *Leukemia*, **2015**, 29, 1960-9	10.7	41
302	How I determine if and when to recommend stopping tyrosine kinase inhibitor treatment for chronic myeloid leukaemia. *British Journal of Haematology*, **2014**, 166, 3-11	4.5	41
301	SHP-1 expression accounts for resistance to imatinib treatment in Philadelphia chromosome-positive cells derived from patients with chronic myeloid leukemia. *Blood*, **2011**, 118, 3634-44	2.2	41
300	Dasatinib treatment for Philadelphia chromosome-positive leukemias: practical considerations. *Cancer*, **2009**, 115, 1381-94	6.4	40
299	Detection of BCR-ABL mutations and resistance to imatinib mesylate. *Methods in Molecular Medicine*, **2006**, 125, 93-106		40

298	Which TKI? An embarrassment of riches for chronic myeloid leukemia patients. *Hematology American Society of Hematology Education Program*, **2013**, 2013, 168-75	3.1	39
297	Imatinib mesylate causes growth plate closure in vivo. *Leukemia*, **2009**, 23, 2155-9	10.7	39
296	Incidence, outcomes, and risk factors of pleural effusion in patients receiving dasatinib therapy for Philadelphia chromosome-positive leukemia. *Haematologica*, **2019**, 104, 93-101	6.6	38
295	Safety and efficacy of switching to nilotinib 400 mg twice daily for patients with chronic myeloid leukemia in chronic phase with suboptimal response or failure on front-line imatinib or nilotinib 300 mg twice daily. *Haematologica*, **2014**, 99, 1204-11	6.6	38
294	Establishment and validation of analytical reference panels for the standardization of quantitative BCR-ABL1 measurements on the international scale. *Clinical Chemistry*, **2013**, 59, 938-48	5.5	38
293	BCR-ABL transcript dynamics support the hypothesis that leukemic stem cells are reduced during imatinib treatment. *Clinical Cancer Research*, **2011**, 17, 6812-21	12.9	37
292	Diagnosis and monitoring of chronic myeloid leukemia by qualitative and quantitative RT-PCR. *Methods in Molecular Medicine*, **2006**, 125, 69-92		37
291	Long-term treatment-free remission of chronic myeloid leukemia with falling levels of residual leukemic cells. *Leukemia*, **2018**, 32, 2572-2579	10.7	37
290	High prevalence of relapse in children with Philadelphia-like acute lymphoblastic leukemia despite risk-adapted treatment. *Haematologica*, **2017**, 102, e490-e493	6.6	36
289	BCR-ABL1 doubling times more reliably assess the dynamics of CML relapse compared with the BCR-ABL1 fold rise: implications for monitoring and management. *Blood*, **2012**, 119, 4264-71	2.2	36
288	OCT-1 activity measurement provides a superior imatinib response predictor than screening for single-nucleotide polymorphisms of OCT-1. *Leukemia*, **2010**, 24, 1962-5	10.7	36
287	Long-term outcomes with frontline nilotinib versus imatinib in newly diagnosed chronic myeloid leukemia in chronic phase: ENESTnd 10-year analysis. *Leukemia*, **2021**, 35, 440-453	10.7	36
286	Long-term response to imatinib is not affected by the initial dose in patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: final update from the Tyrosine Kinase Inhibitor Optimization and Selectivity (TOPS) study. *International Journal of Hematology*, **2014**, 99, 616-24	2.3	35
285	Long-Term Follow-up of Ponatinib Efficacy and Safety in the Phase 2 PACE Trial. *Blood*, **2014**, 124, 3135-3135	21.3	35
284	A pilot study of continuous imatinib vs pulsed imatinib with or without G-CSF in CML patients who have achieved a complete cytogenetic response. *Leukemia*, **2009**, 23, 1199-201	10.7	34
283	Dasatinib inhibits the secretion of TNF-alpha following TLR stimulation in vitro and in vivo. *Experimental Hematology*, **2009**, 37, 1435-44	3.1	33
282	Dasatinib-associated major molecular responses in patients with chronic myeloid leukemia in chronic phase following imatinib failure: response dynamics and predictive value. *Leukemia*, **2009**, 23, 1628-33	10.7	33
281	Apoptosis regulatory gene NEDD2 maps to human chromosome segment 7q34-35, a region frequently affected in haematological neoplasms. *Human Genetics*, **1995**, 95, 641-4	6.3	33

280	A Phase I/II study of nilotinib in Japanese patients with imatinib-resistant or -intolerant Ph+ CML or relapsed/refractory Ph+ ALL. *International Journal of Hematology*, **2009**, 89, 679-88	2.3	32
279	Current issues in chronic myeloid leukemia: monitoring, resistance, and functional cure. *Journal of the National Comprehensive Cancer Network: JNCCN*, **2012**, 10 Suppl 3, S1-S13	7.3	32
278	Imatinib inhibits the functional capacity of cultured human monocytes. *Immunology and Cell Biology* , **2005**, 83, 48-56	5	32
277	ABL kinase inhibitor therapy for CML: baseline assessments and response monitoring. *Hematology American Society of Hematology Education Program*, **2006**, 2006, 211-8	3.1	31
276	HLA-identical sibling donor bone marrow transplantation for chronic myeloid leukaemia in first chronic phase: influence of GVHD prophylaxis on outcome. *British Journal of Haematology*, **1992**, 81, 383-90	4.5	31
275	Sustained deep molecular responses in patients switched to nilotinib due to persistent BCR-ABL1 on imatinib: final ENESTcmr randomized trial results. *Leukemia*, **2017**, 31, 2529-2531	10.7	30
274	Efficacy and Safety of Nilotinib (NIL) vs Imatinib (IM) in Patients (pts) With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP): Long-Term Follow-Up (f/u) of ENESTnd. *Blood*, **2014**, 124, 4541-4541	2.2	30
273	Potential mechanisms of disease progression and management of advanced-phase chronic myeloid leukemia. *Leukemia and Lymphoma*, **2014**, 55, 1451-62	1.9	28
272	Do we have to kill the last CML cell?. *Leukemia*, **2011**, 25, 193-200	10.7	28
271	Guidelines for whole genome bisulphite sequencing of intact and FFPET DNA on the Illumina HiSeq X Ten. *Epigenetics and Chromatin*, **2018**, 11, 24	5.8	27
270	Sustained inhibition of STAT5, but not JAK2, is essential for TKI-induced cell death in chronic myeloid leukemia. *Leukemia*, **2015**, 29, 76-85	10.7	27
269	Nilotinib-mediated inhibition of ABCB1 increases intracellular concentration of dasatinib in CML cells: implications for combination TKI therapy. *Leukemia*, **2010**, 24, 658-60	10.7	27
268	International standardisation of quantitative real-time RT-PCR for BCR-ABL. *Leukemia Research*, **2008**, 32, 505-6	2.7	27
267	Role of allogeneic stem cell transplantation for adult chronic myeloid leukemia in the imatinib era. *Biology of Blood and Marrow Transplantation*, **2006**, 12, 795-807	4.7	26
266	ENESTnd Update: Nilotinib (NIL) Vs Imatinib (IM) In Patients (pts) With Newly Diagnosed Chronic Myeloid Leukemia In Chronic Phase (CML-CP) and The Impact Of Early Molecular Response (EMR) and Sokal Risk At Diagnosis On Long-Term Outcomes. *Blood*, **2013**, 122, 92-92	2.2	26
265	TARGET: a survey of real-world management of chronic myeloid leukaemia across 33 countries. *British Journal of Haematology*, **2020**, 190, 869-876	4.5	25
264	Therapeutic targeting of BCR-ABL: prognostic markers of response and resistance mechanism in chronic myeloid leukaemia. *Critical Reviews in Oncogenesis*, **2012**, 17, 17-30	1.3	25
263	Twenty-year follow-up of newborn screening for patients with muscular dystrophy. *Muscle and Nerve*, **2016**, 53, 570-8	3.4	24

262	The new allosteric inhibitor asciminib is susceptible to resistance mediated by ABCB1 and ABCG2 overexpression. *Oncotarget*, **2018**, 9, 13423-13437	3.3	24
261	Clarithromycin enhances dasatinib-induced cell death in chronic myeloid leukemia cells, by inhibition of late stage autophagy. *Leukemia and Lymphoma*, **2013**, 54, 198-201	1.9	23
260	Nilotinib inhibits the Src-family kinase LCK and T-cell function in vitro. *Journal of Cellular and Molecular Medicine*, **2009**, 13, 599-601	5.6	23
259	A Pivotal Phase 2 Trial of Ponatinib in Patients with Chronic Myeloid Leukemia (CML) and Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ALL) Resistant or Intolerant to Dasatinib or Nilotinib, or with the T315I BCR-ABL Mutation: 12-Month Follow-up of the PACE Trial. *Blood*, **2012**, 120, 163-163	2.2	23
258	Lineage of measurable residual disease in patients with chronic myeloid leukemia in treatment-free remission. *Leukemia*, **2020**, 34, 1052-1061	10.7	23
257	Accumulation of JAK activation loop phosphorylation is linked to type I JAK inhibitor withdrawal syndrome in myelofibrosis. *Science Advances*, **2018**, 4, eaat3834	14.3	23
256	A phase 3, open-label, randomized study of asciminib, a STAMP inhibitor, vs bosutinib in CML after 2 or more prior TKIs. *Blood*, **2021**, 138, 2031-2041	2.2	23
255	Successful treatment-free remission in chronic myeloid leukaemia and its association with reduced immune suppressors and increased natural killer cells. *British Journal of Haematology*, **2020**, 191, 433-441	4.5	22
254	genomic DNA PCR response kinetics during first-line imatinib treatment of chronic myeloid leukemia. *Haematologica*, **2018**, 103, 2026-2032	6.6	22
253	Many BCR-ABL1 compound mutations reported in chronic myeloid leukemia patients may actually be artifacts due to PCR-mediated recombination. *Blood*, **2014**, 124, 153-5	2.2	22
252	Prediction of outcomes in patients with Ph+ chronic myeloid leukemia in chronic phase treated with nilotinib after imatinib resistance/intolerance. *Leukemia*, **2013**, 27, 907-13	10.7	22
251	TGF-β and IL-6 plasma levels selectively identify CML patients who fail to achieve an early molecular response or progress in the first year of therapy. *Leukemia*, **2016**, 30, 1263-72	10.7	21
250	Degree of kinase inhibition achieved in vitro by imatinib and nilotinib is decreased by high levels of ABCB1 but not ABCG2. *Leukemia and Lymphoma*, **2013**, 54, 569-78	1.9	21
249	Optimizing outcomes for patients with advanced disease in chronic myelogenous leukemia. *Seminars in Oncology*, **2008**, 35, S1-17; quiz S18-20	5.5	21
248	Dual transcription of b2a2 and b3a2 BCR-ABL transcripts in chronic myeloid leukaemia is confined to patients with a linked polymorphism within the BCR gene. *British Journal of Haematology*, **2002**, 117, 875-7	4.5	21
247	Early BCR-ABL1 kinetics are predictive of subsequent achievement of treatment-free remission in chronic myeloid leukemia. *Blood*, **2021**, 137, 1196-1207	2.2	21
246	Reduced CD62L Expression on T Cells and Increased Soluble CD62L Levels Predict Molecular Response to Tyrosine Kinase Inhibitor Therapy in Early Chronic-Phase Chronic Myelogenous Leukemia. *Journal of Clinical Oncology*, **2017**, 35, 175-184	2.2	20
245	Ponatinib is not transported by ABCB1, ABCG2 or OCT-1 in CML cells. *Leukemia*, **2015**, 29, 1792-4	10.7	20

244	Relapse of BCR-ABL1-like ALL mediated by the ABL1 kinase domain mutation T315I following initial response to dasatinib treatment. *Leukemia*, **2015**, 29, 230-2	10.7	20
243	A dual role for the N-terminal domain of the IL-3 receptor in cell signalling. *Nature Communications*, **2018**, 9, 386	17.4	20
242	Concurrent use of proton pump inhibitors or H2 blockers did not adversely affect nilotinib efficacy in patients with chronic myeloid leukemia. *Cancer Chemotherapy and Pharmacology*, **2012**, 70, 345-50	3.5	20
241	Mutational analysis in chronic myeloid leukemia: when and what to do?. *Current Opinion in Hematology*, **2011**, 18, 111-6	3.3	20
240	ABL001, a Potent, Allosteric Inhibitor of BCR-ABL, Exhibits Safety and Promising Single- Agent Activity in a Phase I Study of Patients with CML with Failure of Prior TKI Therapy. *Blood*, **2015**, 126, 138-138	2.2	20
239	Gene expression signature that predicts early molecular response failure in chronic-phase CML patients on frontline imatinib. *Blood Advances*, **2019**, 3, 1610-1621	7.8	20
238	Treatment-free remission in patients with chronic myeloid leukaemia. *Nature Reviews Clinical Oncology*, **2020**, 17, 493-503	19.4	19
237	A DNA real-time quantitative PCR method suitable for routine monitoring of low levels of minimal residual disease in chronic myeloid leukemia. *Journal of Molecular Diagnostics*, **2015**, 17, 185-92	5.1	19
236	Prospective histomorphometric and DXA evaluation of bone remodeling in imatinib-treated CML patients: evidence for site-specific skeletal effects. *Journal of Clinical Endocrinology and Metabolism* , **2013**, 98, 67-76	5.6	19
235	Protein kinase activity of phosphoinositide 3-kinase regulates cytokine-dependent cell survival. *PLoS Biology*, **2013**, 11, e1001515	9.7	19
234	ABCB1 Overexpression Is a Key Initiator of Resistance to Tyrosine Kinase Inhibitors in CML Cell Lines. *PLoS ONE*, **2016**, 11, e0161470	3.7	19
233	KIR2DL5B genotype predicts outcomes in CML patients treated with response-directed sequential imatinib/nilotinib strategy. *Blood*, **2015**, 126, 2720-3	2.2	18
232	The poor response to imatinib observed in CML patients with low OCT-1 activity is not attributable to lower uptake of imatinib into their CD34+ cells. *Blood*, **2010**, 116, 2776-8	2.2	18
231	Suboptimal responses in chronic myeloid leukemia: implications and management strategies. *Cancer*, **2012**, 118, 1181-91	6.4	17
230	Differential expression of MUC4, GPR110 and IL2RA defines two groups of CRLF2-rearranged acute lymphoblastic leukemia patients with distinct secondary lesions. *Cancer Letters*, **2017**, 408, 92-101	9.9	17
229	A Phase III, Randomized, Open-Label Study of 400 Mg Versus 800 Mg of Imatinib Mesylate (IM) in Patients (pts) with Newly Diagnosed, Previously Untreated Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Using Molecular Endpoints: 1-Year Results of TOPS (Tyrosine Kinase Inhibitor Optimization and Selectivity) Study. *Blood*, **2008**, 112, 335-335	2.2	17
228	ENESTnd Update: Continued Superiority of Nilotinib Versus Imatinib In Patients with Newly Diagnosed Chronic Myeloid Leukemia In Chronic Phase (CML-CP). *Blood*, **2010**, 116, 207-207	2.2	17
227	Distribution of genomic breakpoints in chronic myeloid leukemia: analysis of 308 patients. *Leukemia*, **2013**, 27, 2105-7	10.7	16

226	Contrasting effects of diclofenac and ibuprofen on active imatinib uptake into leukaemic cells. *British Journal of Cancer*, **2012**, 106, 1772-8	8.7	16
225	Classification of patients with chronic myeloid leukemia on basis of BCR-ABL transcript level at 3 months fails to identify patients with low organic cation transporter-1 activity destined to have poor imatinib response. *Journal of Clinical Oncology*, **2012**, 30, 1144-5; author reply 1145-6	2.2	15
224	Efficacy of Dasatinib in Patients with Chronic-Phase Chronic Myelogenous Leukemia with Resistance or Intolerance to Imatinib: 2-Year Follow-Up Data from START-C (CA180-013).. *Blood*, **2007**, 110, 734-734	2.2	15
223	Update On Imatinib-Resistant Chronic Myeloid Leukemia Patients in Chronic Phase (CML-CP) On Nilotinib Therapy at 24 Months: Clinical Response, Safety, and Long-Term Outcomes.. *Blood*, **2009**, 114, 1129-1129	2.2	15
222	Nilotinib Demonstrates Superior Efficacy Compared with Imatinib in Patients with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase: Results From the International Randomized Phase III ENESTnd Trial. *Blood*, **2009**, 114, LBA-1-LBA-1	2.2	15
221	Modeling the safe minimum frequency of molecular monitoring for CML patients attempting treatment-free remission. *Blood*, **2019**, 134, 85-89	2.2	14
220	Pre-B acute lymphoblastic leukaemia recurrent fusion, EP300-ZNF384, is associated with a distinct gene expression. *British Journal of Cancer*, **2018**, 118, 1000-1004	8.7	14
219	BCR-ABL1 kinase domain mutations may persist at very low levels for many years and lead to subsequent TKI resistance. *British Journal of Cancer*, **2013**, 109, 1593-8	8.7	14
218	Protective role for properdin in progression of experimental murine atherosclerosis. *PLoS ONE*, **2014**, 9, e92404	3.7	14
217	Efficacy and Safety of Nilotinib In Chronic Phase (CP) Chronic Myeloid Leukemia (CML) Patients (Pts) with Type 2 Diabetes In the ENESTnd Trial.. *Blood*, **2010**, 116, 3430-3430	2.2	14
216	Role of the □Common (□) Family of Cytokines in Health and Disease. *Cold Spring Harbor Perspectives in Biology*, **2018**, 10,	10.2	13
215	ABCC6 plays a significant role in the transport of nilotinib and dasatinib, and contributes to TKI resistance in vitro, in both cell lines and primary patient mononuclear cells. *PLoS ONE*, **2018**, 13, e0192180	3.7	13
214	Rapid initial decline in BCR-ABL1 is associated with superior responses to second-line nilotinib in patients with chronic-phase chronic myeloid leukemia. *BMC Cancer*, **2013**, 13, 173	4.8	13
213	Dasatinib alters the metastatic phenotype of B16-OVA melanoma in vivo. *Cancer Biology and Therapy*, **2010**, 10, 715-27	4.6	13
212	Short-term intense Bcr-Abl kinase inhibition with nilotinib is adequate to trigger cell death in BCR-ABL(+) cells. *Leukemia*, **2009**, 23, 1205-6	10.7	13
211	Continuing Reduction in Level of Residual Disease after 4 Years in Patients with CML in Chronic Phase Responding to First-Line Imatinib (IM) in the IRIS Study.. *Blood*, **2005**, 106, 163-163	2.2	13
210	Enestnd 4-Year (y) Update: Continued Superiority of Nilotinib Vs Imatinib in Patients (pts) with Newly Diagnosed Philadelphia Chromosome□Positive (Ph+) Chronic Myeloid Leukemia in Chronic Phase (CML-CP). *Blood*, **2012**, 120, 1676-1676	2.2	13
209	Dynamics of chronic myeloid leukemia response to dasatinib, nilotinib, and high-dose imatinib. *Haematologica*, **2014**, 99, 1701-9	6.6	12

208	Drug-interaction studies evaluating T-cell proliferation reveal distinct activity of dasatinib and imatinib in combination with cyclosporine A. *Experimental Hematology*, **2012**, 40, 612-21.e6	3.1	12
207	OCT-1 function varies with cell lineage but is not influenced by BCR-ABL. *Haematologica*, **2011**, 96, 213-20	6.6	12
206	Reduction of BCR-ABL Transcript Levels at 6, 12, and 18 Months (mo) Correlates with Long-Term Outcomes on Imatinib (IM) at 72 Mo: An Analysis from the International Randomized Study of Interferon versus STI571 (IRIS) in Patients (pts) with Chronic Phase Chronic Myeloid Leukemia (CML-CP). *Blood*, **2008**, 112, 334-334	2.2	12
205	Expanded Phase 1 Study of ABL001, a Potent, Allosteric Inhibitor of BCR-ABL, Reveals Significant and Durable Responses in Patients with CML-Chronic Phase with Failure of Prior TKI Therapy. *Blood*, **2016**, 128, 625-625	2.2	12
204	Molecular monitoring in CML: how deep? How often? How should it influence therapy?. *Hematology American Society of Hematology Education Program*, **2018**, 2018, 168-176	3.1	12
203	Aberrant RAG-mediated recombination contributes to multiple structural rearrangements in lymphoid blast crisis of chronic myeloid leukemia. *Leukemia*, **2020**, 34, 2051-2063	10.7	11
202	Low incidence of peripheral arterial disease in patients receiving dasatinib in clinical trials. *Leukemia*, **2016**, 30, 1593-6	10.7	11
201	Dasatinib targets chronic myeloid leukemia-CD34+ progenitors as effectively as it targets mature cells. *Haematologica*, **2013**, 98, 896-900	6.6	11
200	Managing imatinib resistance in chronic myeloid leukaemia. *Current Opinion in Hematology*, **2010**, 17, 97-103	3.3	11
199	Reverse transcription with random pentadecamer primers improves the detection limit of a quantitative PCR assay for BCR-ABL transcripts in chronic myeloid leukemia: implications for defining sensitivity in minimal residual disease. *Clinical Chemistry*, **2008**, 54, 1568-71	5.5	11
198	Monitoring of minimal residual disease in chronic myeloid leukemia. *Hematology/Oncology Clinics of North America*, **2004**, 18, 657-70, ix-x	3.1	11
197	Long Term Follow up of Patients with CML in Chronic Phase Treated with First-Line Imatinib Suggests That Earlier Achievement of a Major Molecular Response Leads to Greater Stability of Response.. *Blood*, **2008**, 112, 2113-2113	2.2	11
196	CML Patients with Low OCT-1 Activity Achieve Better Molecular Responses on High Dose Imatinib Than on Standard Dose. Those with High OCT-1 Activity Have Excellent Responses on Either Dose: A TOPS Correlative Study. *Blood*, **2008**, 112, 3187-3187	2.2	11
195	24 Months Update of the TOPS Study: a Phase III, Randomized, Open-Label Study of 400mg/d (SD-IM) Versus 800mg/d (HD-IM) of Imatinib Mesylate (IM) in Patients (Pts) with Newly Diagnosed, Previously Untreated Chronic Myeloid Leukemia in Chronic Phase (CML-CP).. *Blood*, **2009**, 114, 337-337	2.2	11
194	Clinical impact of dose modification and dose intensity on response to ponatinib (PON) in patients (pts) with Philadelphia chromosome-positive (Ph+) leukemias.. *Journal of Clinical Oncology*, **2014**, 32, 7084-7084	2.2	11
193	Low GFI1 expression in white blood cells of CP-CML patients at diagnosis is strongly associated with subsequent blastic transformation. *Leukemia*, **2013**, 27, 1427-30	10.7	10
192	Nilotinib dose-optimization in newly diagnosed chronic myeloid leukaemia in chronic phase: final results from ENESTxtnd. *British Journal of Haematology*, **2017**, 179, 219-228	4.5	10
191	Nilotinib does not significantly reduce imatinib OCT-1 activity in either cell lines or primary CML cells. *Leukemia*, **2010**, 24, 855-7	10.7	10

190	Efficacy and Safety Results from ASCEMBL, a Multicenter, Open-Label, Phase 3 Study of Asciminib, a First-in-Class STAMP Inhibitor, vs Bosutinib (BOS) in Patients (Pts) with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Previously Treated with ≥ Tyrosine Kinase Inhibitors (TKIs. *Blood*, **2020**, 136, LBA-4-LBA-4	2.2	10
189	Outcome of Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Based On Early Molecular Response and Factors Associated with Early Response: 4-Year Follow-up Data From Enestnd (Evaluating Nilotinib Efficacy and Safety in Clinical Trials Newly Diagnosed Patients). *Blood*, **2012**, 120, 167-167	2.2	10
188	Incidence of Hyperglycemia by 3 Years in Patients (Pts) with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Treated with Nilotinib (NIL) or Imatinib (IM) in ENESTnd. *Blood*, **2012**, 120, 1686-1686	2.2	10
187	Treatment-free remission (TFR) following nilotinib (NIL) in patients (pts) with chronic myeloid leukemia in chronic phase (CML-CP): ENESTfreedom, ENESTop, ENESTgoal, and ENESTpath.. *Journal of Clinical Oncology*, **2014**, 32, TPS7124-TPS7124	2.2	10
186	and germ line variants predict response and identify CML patients with the greatest risk of imatinib failure. *Blood Advances*, **2017**, 1, 1369-1381	7.8	9
185	NPM1 mutations occur rarely or not at all in chronic myeloid leukaemia patients in chronic phase or blast crisis. *Leukemia*, **2013**, 27, 489-90	10.7	9
184	OCT-1 as a determinant of response to antileukemic treatment. *Clinical Pharmacology and Therapeutics*, **2011**, 89, 608-11	6.1	9
183	Current and emerging tests for the laboratory monitoring of chronic myeloid leukaemia and related disorders. *Pathology*, **2008**, 40, 231-46	1.6	9
182	Mutation screening of the c-MYB negative regulatory domain in acute and chronic myeloid leukaemia. *British Journal of Haematology*, **2001**, 114, 632-4	4.5	9
181	Cardiac Safety Profile of Imatinib and Nilotinib In Patients (pts) with Newly Diagnosed Chronic Myeloid Leukemia In Chronic Phase (CML-CP): Results From ENESTnd. *Blood*, **2010**, 116, 2291-2291	2.2	9
180	Upfront Imatinib Therapy in CML Patients with Rapid Switching to Nilotinib for Failure to Achieve Molecular Targets or Intolerance Achieves High Overall Rates of Molecular Response and a Low Risk of Progression - An Update of the TIDEL-II Trial. *Blood*, **2011**, 118, 451-451	2.2	9
179	CYP2C8 Genotype Significantly Alters Imatinib Metabolism in Chronic Myeloid Leukaemia Patients. *Clinical Pharmacokinetics*, **2017**, 56, 977-985	6.2	8
178	Efficacy and safety of nilotinib 300 mg twice daily in patients with chronic myeloid leukemia in chronic phase who are intolerant to prior tyrosine kinase inhibitors: Results from the Phase IIIb ENESTswift study. *Leukemia Research*, **2018**, 67, 109-115	2.7	8
177	A novel somatic JAK2 kinase-domain mutation in pediatric acute lymphoblastic leukemia with rapid on-treatment development of LOH. *Cancer Genetics*, **2017**, 216-217, 86-90	2.3	8
176	First Approved Kinase Inhibitor for AML. *Cell*, **2017**, 171, 981	56.2	8
175	Reply to NWhat do we mean by sensitivity when we talk about detecting minimal residual disease?N by Steinbach and Debatin. *Leukemia*, **2009**, 23, 819-20; author reply 820	10.7	8
174	Measuring minimal residual disease in chronic myeloid leukemia: fluorescence in situ hybridization and polymerase chain reaction. *Clinical Lymphoma and Myeloma*, **2009**, 9 Suppl 3, S266-71		8
173	Ph+ ALL: resistance seeds sown early. *Blood*, **2007**, 110, 472-472	2.2	8

172	Increasing Frequency and Marked Stability of Complete Molecular Response Is Observed in Imatinib-Treated CML Patients with Long-Term Follow Up.. *Blood*, **2006**, 108, 430-430	2.2	8
171	Nilotinib Versus Imatinib in Patients (pts) with Newly Diagnosed Philadelphia Chromosome-Positive (Ph+) Chronic Myeloid Leukemia in Chronic Phase (CML-CP): ENESTnd 36-Month (mo) Follow-up. *Blood*, **2011**, 118, 452-452	2.2	8
170	Peripheral Arterial Occlusive Disease (PAOD) In Patients (Pts) Receiving Dasatinib: Experience Across Multiple Clinical Trials. *Blood*, **2013**, 122, 1489-1489	2.2	8
169	Ponatinib Efficacy and Safety in Patients with the T315I Mutation: Long-Term Follow-up of Phase 1 and Phase 2 (PACE) Trials. *Blood*, **2014**, 124, 4552-4552	2.2	8
168	Molecular monitoring in CML: how deep? How often? How should it influence therapy?. *Blood*, **2018**, 132, 2125-2133	2.2	8
167	Increased peroxisome proliferator-activated receptor activity reduces imatinib uptake and efficacy in chronic myeloid leukemia mononuclear cells. *Haematologica*, **2017**, 102, 843-853	6.6	7
166	Lenalidomide maintenance treatment after imatinib discontinuation: results of a phase 1 clinical trial in chronic myeloid leukaemia. *British Journal of Haematology*, **2019**, 186, e56-e60	4.5	7
165	Patients with low OCT-1 activity and high ABCB1 fold rise have poor long-term outcomes in response to tyrosine kinase inhibitor therapy. *Leukemia*, **2018**, 32, 2288-2291	10.7	7
164	BCR-ABL1 expression, RT-qPCR and treatment decisions in chronic myeloid leukaemia. *Journal of Clinical Pathology*, **2016**, 69, 817-21	3.9	7
163	A Method for Next-Generation Sequencing of Paired Diagnostic and Remission Samples to Detect Mitochondrial DNA Mutations Associated with Leukemia. *Journal of Molecular Diagnostics*, **2017**, 19, 711-721	5.1	7
162	Proton pump inhibitors significantly increase the intracellular concentration of nilotinib, but not imatinib in target CML cells. *Leukemia*, **2013**, 27, 1201-4	10.7	7
161	Predicting the response of CML patients to tyrosine kinase inhibitor therapy. *Current Hematologic Malignancy Reports*, **2011**, 6, 88-95	4.4	7
160	Practical considerations for monitoring patients with chronic myeloid leukemia. *Seminars in Hematology*, **2010**, 47, 327-34	4	7
159	Higher-Dose Imatinib (600 mg/Day) with Selective Intensification in Newly Diagnosed CML Patients in Chronic Phase; Cytogenetic Response Rates at 12 Months Are Superior to IRIS.. *Blood*, **2004**, 104, 1001-1001	2.2	7
158	Maintenance of Imatinib Dose Intensity in the First Six Months of Therapy for Newly Diagnosed Patients with CML Is Predictive of Molecular Response, Independent of the Ability To Increase Dose at a Later Point.. *Blood*, **2005**, 106, 164-164	2.2	7
157	The Majority of Chronic Myeloid Leukaemia Patients Who Cease Imatinib after Achieving a Sustained Complete Molecular Response (CMR) Remain in CMR, and Any Relapses Occur Early.. *Blood*, **2008**, 112, 1102-1102	2.2	7
156	Living with CML: is death no longer the end (point)?. *Blood*, **2015**, 126, 2-4	2.2	6
155	Safety and efficacy of pulsed imatinib with or without G-CSF versus continuous imatinib in chronic phase chronic myeloid leukaemia patients at 5 years follow-up. *British Journal of Haematology*, **2013**, 163, 674-6	4.5	6

154	Predicting the response of CML patients to tyrosine kinase inhibitor therapy. *Current Hematologic Malignancy Reports*, **2009**, 4, 59-65	4.4	6
153	Combination of Nilotinib and Pegylated Interferon Alfa-2b Results in High Molecular Response Rates in Chronic Phase CML: Interim Results of the ALLG CML 11 Pinnacle Study. *Blood*, **2018**, 132, 459-459	2.2	6
152	Dasatinib Efficacy in Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) and Pre-Existing BCR-ABL Mutations. *Blood*, **2008**, 112, 449-449	2.2	6
151	Multivariate Analyses of the Clinical and Molecular Parameters Associated with Efficacy and Safety in Patients with Chronic Myeloid Leukemia (CML) and Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ ALL) Treated with Ponatinib in the PACE Trial. *Blood*, **2012**, 120, 3747-3747	2.2	6
150	Efficacy and Safety of Ponatinib in Patients with Accelerated Phase or Blast Phase Chronic Myeloid Leukemia (AP-CML or BP-CML) or Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ ALL): 12-Month Follow-up of the PACE Trial. *Blood*, **2012**, 120, 915-915	2.2	6
149	Impact Of Baseline (BL) Mutations, Including Low-Level and Compound Mutations, On Ponatinib Response and End Of Treatment (EOT) Mutation Analysis In Patients (Pts) With Chronic Phase Chronic Myeloid Leukemia (CP-CML). *Blood*, **2013**, 122, 652-652	2.2	6
148	Five-year results of the ponatinib phase II PACE trial in heavily pretreated CP-CML patients (pts).. *Journal of Clinical Oncology*, **2017**, 35, 7012-7012	2.2	6
147	Modelling ponatinib resistance in tyrosine kinase inhibitor-naïve and dasatinib resistant + cell lines. *Oncotarget*, **2018**, 9, 34735-34747	3.3	6
146	The effect of co-occurring lesions on leukaemogenesis and drug response in T-ALL and ETP-ALL. *British Journal of Cancer*, **2020**, 122, 455-464	8.7	6
145	Genomic translocation breakpoint sequences are conserved in BCR-ABL1 cell lines despite the presence of amplification. *Cancer Genetics and Cytogenetics*, **2009**, 189, 138-9		5
144	Daclizumab has poor efficacy in steroid-refractory severe acute graft-versus-host disease: a single centre experience with 12 allograft patients. *Bone Marrow Transplantation*, **2008**, 41, 409-10	4.4	5
143	Efficacy and safety of imatinib in patients with chronic myeloid leukemia and complete or near-complete cytogenetic response to interferon-alpha. *Cancer*, **2007**, 110, 801-8	6.4	5
142	Asciminib, a Specific Allosteric BCR-ABL1 Inhibitor, in Patients with Chronic Myeloid Leukemia Carrying the T315I Mutation in a Phase 1 Trial. *Blood*, **2018**, 132, 792-792	2.2	5
141	Dasatinib-Associated Major Molecular Responses Are Rapidly Achieved in Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Following Resistance, Suboptimal Response, or Intolerance on Imatinib.. *Blood*, **2008**, 112, 1095-1095	2.2	5
140	Imatinib (IM) Pharmacokinetic (PK) Exposure and Its Correlation with Clinical Outcome in Patients with Chronic-Phase Chronic Myeloid Leukemia (CML-CP) for 400 Mg and 800 Mg Daily Doses (Tyrosine Kinase Dose Optimization Study [TOPS]). *Blood*, **2008**, 112, 447-447	2.2	5
139	Nilotinib Shows Safety and Efficacy in Older Patients (≥65 years) with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase Comparable with That in Younger Patients with Chronic Myeloid Leukemia in Chronic Phase: Results From ENESTnd,. *Blood*, **2011**, 118, 3768-3768	2.2	5
138	The Impact of Ponatinib Versus Allogeneic Stem Cell Transplant (SCT) on Outcomes in Patients with Chronic Myeloid Leukemia (CML) or Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ ALL) with the T315I Mutation. *Blood*, **2015**, 126, 480-480	2.2	5
137	Nilotinib versus imatinib in patients (pts) with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP): ENESTnd 4-year (y) update.. *Journal of Clinical Oncology*, **2013**, 31, 7052-7052	2.2	5

136	ENESTop 192-week results: Treatment-free remission (TFR) in patients (pts) with chronic myeloid leukemia in chronic phase (CML-CP) after stopping second-line (2L) nilotinib (NIL).. *Journal of Clinical Oncology*, **2019**, 37, 7005-7005	2.2	5
135	Long-term treatment-free remission in patients with chronic myeloid leukemia after second-line nilotinib: ENESTop 5-year update. *Leukemia*, **2021**, 35, 1631-1642	10.7	5
134	Strategies for the treatment of imatinib-resistant chronic myeloid leukemia. *Clinical Advances in Hematology and Oncology*, **2003**, 1, 538-45, 559	0.6	5
133	Targeted therapies: Remembrance of things past - discontinuation of second-generation TKI therapy for CML. *Nature Reviews Clinical Oncology*, **2017**, 14, 201-202	19.4	4
132	Imatinib-induced gastric antral vascular ectasia in three patients with chronic myeloid leukaemia. *International Journal of Hematology*, **2015**, 102, 639-42	2.3	4
131	Elevated PTPN2 expression is associated with inferior molecular response in de-novo chronic myeloid leukaemia patients. *Leukemia*, **2014**, 28, 702-5	10.7	4
130	Clinical strategies to achieve an early and successful response to tyrosine kinase inhibitor therapy. *Seminars in Hematology*, **2009**, 46, S11-5	4	4
129	Major Cytogenetic Responses to BMS-354825 in Patients with Chronic Myeloid Leukemia Are Associated with a One to Two Log Reduction in BCR-ABL Transcript.. *Blood*, **2004**, 104, 1008-1008	2.2	4
128	Selective Escalation of Imatinib Therapy and Early Switching to Nilotinib In De Novo Chronic Phase CML Patients: Interim Results From the TIDEL-II Trial. *Blood*, **2010**, 116, 209-209	2.2	4
127	A Review of Mutation Analysis In the TOPS Trial of Standard Dose Versus High Dose IM In CML Suggests That Refinements to the ELN Recommendations for Mutation Screening May Be Appropriate. *Blood*, **2010**, 116, 889-889	2.2	4
126	Nilotinib in Imatinib-Resistant or -Intolerant Patients (pts) with Chronic Myeloid Leukemia in Chronic Phase (CML-CP): 48-Month Follow-up Results of a Phase 2 Study,. *Blood*, **2011**, 118, 3770-3770	2.2	4
125	Early Molecular Response and Female Sex Strongly Predict Achievement of Stable Undetectable BCR-ABL1, a Criterion for Imatinib Discontinuation in Patients with CML. *Blood*, **2012**, 120, 165-165	2.2	4
124	Molecular Responses with Ponatinib in Patients with Philadelphia Chromosome Positive (Ph+) Leukemia: Results From the PACE Trial. *Blood*, **2012**, 120, 3763-3763	2.2	4
123	Early Switch to Nilotinib Does Not Overcome the Adverse Outcome for CML Patients Failing to Achieve Early Molecular Response On Imatinib, Despite Excellent Overall Outcomes in the TIDEL II Trial. *Blood*, **2012**, 120, 3771-3771	2.2	4
122	Ponatinib In Heavily Pretreated Patients With Chronic Phase Chronic Myeloid Leukemia (CP-CML): Management Of Adverse Events (AEs). *Blood*, **2013**, 122, 1496-1496	2.2	4
121	Treatment-free remission (TFR) in patients (pts) with chronic myeloid leukemia in chronic phase (CML-CP) treated with second-line nilotinib (NIL): First results from the ENESTop study.. *Journal of Clinical Oncology*, **2016**, 34, 7054-7054	2.2	4
120	An imatinib-only window followed by imatinib and chemotherapy for Philadelphia chromosome-positive acute leukemia: long-term results of the CMLALL1 trial. *Leukemia and Lymphoma*, **2015**, 56, 630-8	1.9	3
119	Development of Asciminib, a Novel Allosteric Inhibitor of BCR-ABL1.. *Critical Reviews in Oncology/Hematology*, **2022**, 171, 103580	7	3

118	Azacytidine Sensitizes AML Cells for Effective Elimination By CD123 CAR T-Cells. *Blood*, **2019**, 134, 3904-3904	2.2	3
117	Analyses of Predictors of Durable Treatment-Free Remission in Patients with Chronic Myeloid Leukemia in Chronic Phase Following Frontline or Second-Line Nilotinib. *Blood*, **2019**, 134, 2932-2932	2.2	3
116	ENESTop 5-Year Update: Durability of Treatment-Free Remission Following Second-Line Nilotinib and Exploratory Analysis of Molecular Response Regain after Nilotinib Re-Initiation in Patients with Chronic Myeloid Leukemia. *Blood*, **2020**, 136, 29-30	2.2	3
115	Genome-Wide Analysis of Genetic Alterations in Chronic Myelogenous Leukemia.. *Blood*, **2008**, 112, 1089-1089	2.2	3
114	Reduced Activity of the OCT-1 Protein in Primitive CML Cells: A Likely Determinant of Stem Cell Resistance in Imatinib Treated CML Patients. *Blood*, **2008**, 112, 196-196	2.2	3
113	Molecular Response at 3 Months On Nilotinib Therapy Predicts Response and Long-Term Outcomes in Patients with Imatinib-Resistant or -Intolerant Chronic Myeloid Leukemia in Chronic Phase (CML-CP).. *Blood*, **2009**, 114, 3292-3292	2.2	3
112	Nilotinib Lowers the Incidence of BCR-ABL Mutations and Improves the Molecular Response Kinetics Compared with Imatinib in Patients (Pts) with Newly Diagnosed Chronic Myeloid Leukemia (CML).. *Blood*, **2010**, 116, 3431-3431	2.2	3
111	Detection of BCR-ABL1 Compound and Polyclonal Mutants in Chronic Myeloid Leukemia Patients Using a Novel Next Generation Sequencing Approach That Minimises PCR and Sequencing Errors. *Blood*, **2014**, 124, 399-399	2.2	3
110	Treatment-Free Remission (TFR) Eligibility in Patients (pts) with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) and Residual Disease on Long-Term Imatinib (IM) Who Switched to Second-Line Nilotinib (NIL). *Blood*, **2015**, 126, 4029-4029	2.2	3
109	Long-term treatment-free remission (TFR) in patients (pts) with chronic myeloid leukemia in chronic phase (CML-CP) after stopping second-line (2L) nilotinib: ENESTop 144-wk results.. *Journal of Clinical Oncology*, **2018**, 36, 7003-7003	2.2	3
108	Efficacy and Safety Results from Ascembl, a Multicenter, Open-Label, Phase 3 Study of Asciminib, a First-in-Class STAMP Inhibitor, Vs Bosutinib in Patients with Chronic Myeloid Leukemia in Chronic Phase after ≥ Prior Tyrosine Kinase Inhibitors: Update after 48 Weeks. *Blood*, **2021**, 138, 310-310	2.2	3
107	Monitoring Disease Response **2007**, 143-164		3
106	Widespread Aberrant Alternative Splicing despite Molecular Remission in Chronic Myeloid Leukaemia Patients. *Cancers*, **2020**, 12,	6.6	3
105	Clinical utility of genomic DNA Q-PCR for the monitoring of a patient with atypical e19a2 transcripts in chronic myeloid leukemia. *Leukemia and Lymphoma*, **2020**, 61, 2527-2529	1.9	2
104	Modelling Predictors of Molecular Response to Frontline Imatinib for Patients with Chronic Myeloid Leukaemia. *PLoS ONE*, **2017**, 12, e0168947	3.7	2
103	Bone marrow fibrosis associated with long-term imatinib therapy: resolution after switching to a second-generation TKI. *Blood Advances*, **2019**, 3, 370-374	7.8	2
102	Sudden blast crisis in chronic myeloid leukemia treated with tyrosine kinase inhibitors. *Leukemia and Lymphoma*, **2012**, 53, 1251-2	1.9	2
101	How complete is "complete" molecular response in imatinib-treated chronic myeloid leukemia?. *Leukemia and Lymphoma*, **2008**, 49, 1230-1	1.9	2

100	Mutated Cancer-Related Genes Detected at Diagnosis of CML and a Novel Class of Variant Associated with the Philadelphia Translocation Are Both Independent Predictors of Inferior Outcomes. *Blood*, **2020**, 136, 46-47	2.2	2
99	Major Molecular Responses to Dasatinib (BMS-354825) Are Observed in Imatinib-Resistant Late Stage Chronic and Advanced CML Patients: Impact and Fate of Imatinib-Resistant Clones in Dasatinib-Treated Patients.. *Blood*, **2005**, 106, 437-437	2.2	2
98	ABCB1 Overexpression May Predispose Imatinib Treated CML Patients to the Development of Abl Kinase Domain Mutations, and May Be an Important Contributor to Acquired Resistance.. *Blood*, **2006**, 108, 2144-2144	2.2	2
97	The Most Common Dasatinib-Resistant BCR-ABL Kinase Domain Mutations in Patients with Chronic Myeloid Leukemia Are Sensitive to VX-680: Rationale for Early Combination Kinase Inhibitor Therapy.. *Blood*, **2006**, 108, 2175-2175	2.2	2
96	Validation of the International Scale for Measurement of BCR-ABL by RQ-PCR Based on Deriving Laboratory-Specific Conversion Factors.. *Blood*, **2007**, 110, 1013-1013	2.2	2
95	A Phase 3 Pilot Study of Continuous Imatinib Versus Pulsed Imatinib with or without G-CSF in Patients with Chronic Phase CML Who Have Achieved a Complete Cytogenetic Response to Imatinib.. *Blood*, **2007**, 110, 1033-1033	2.2	2
94	The Initial Molecular Response of Chronic Phase CML Patients Treated with Second Generation ABL Inhibitor Therapy after Imatinib Failure Can Predict Inadequate Response and Provide Indications for Rational Mutation Screening. *Blood*, **2008**, 112, 331-331	2.2	2
93	Comparison of Steady-State Imatinib (IM) Trough Levels, Clinical Response, and Safety Between Caucasian and Asian Patients with Chronic Lyeloid Leukemia in Chronic Phase (CML-CP) Treated with 400mg and 800mg Daily Doses of IM in the Tyrosine Kinase Inhibitor Optimization and	2.2	2
92	Response and Outcomes to Nilotinib at 24 Months in Imatinib-Resistant Chronic Myeloid Leukemia Patients in Chronic Phase (CML-CP) and Accelerated Phase (CML-AP) with and without BCR-ABL Mutations.. *Blood*, **2009**, 114, 1130-1130	2.2	2
91	A Worldwide Observational Registry Collecting Longitudinal Data on Management of Chronic Myeloid Leukemia Patients (The WORLD CML Registry) 2nd Annual Interim Analysis. *Blood*, **2010**, 116, 2292-2292	2.2	2
90	Imatinib Dose Interruption in Responding CML Patients Is Associated with Characteristic BCR-ABL Kinetics, Which Could Help to Differentiate Non-Adherence From Drug Resistance. *Blood*, **2011**, 118, 113-113	2.2	2
89	Results From the ENESTnd Extension Study: Efficacy and Safety of Patients (pts) with Chronic Myeloid Leukemia in Chronic Phase (CML-CP), Treated with Nilotinib 400 Mg Twice Daily (BID) After Suboptimal Response (SoR) or Treatment Failure (TF) to Imatinib 400 Mg Once Daily (QD) or Nilotinib 300 Mg BID. *Blood*, **2011**, 118, 114-114	2.2	2
88	Commitment of CML Cells to Apoptotic Cell Death Depends On the Length of Exposure to Das and the Level of STAT5 Activity. *Blood*, **2012**, 120, 3736-3736	2.2	2
87	Switching to Nilotinib Is Associated with Continued Deeper Molecular Responses in CML-CP Patients with Minimal Residual Disease After 2 Years On Imatinib: Enestcmr 2-Year Follow-up Results. *Blood*, **2012**, 120, 694-694	2.2	2
86	Dose-Optimized Nilotinib (NIL) in Patients (Pts) with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP): Final Results from ENESTxtnd Study. *Blood*, **2015**, 126, 344-344	2.2	2
85	The Allosteric Inhibitor ABL001 Is Susceptible to Resistance in Vitro Mediated By Overexpression of the Drug Efflux Transporters ABCB1 and ABCG2. *Blood*, **2015**, 126, 4841-4841	2.2	2
84	Novel Fusion Genes at CML Diagnosis Reveal a Complex Pattern of Genomic Rearrangements and Sequence Inversions Associated with the Philadelphia Chromosome in Patients with Early Blast Crisis. *Blood*, **2016**, 128, 1219-1219	2.2	2
83	Nilotinib versus imatinib in patients (pts) with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP): ENESTnd 3-year (yr) follow-up (f/u).. *Journal of Clinical Oncology*, **2012**, 30, 6509-6509	2.2	2

82	Impact of baseline mutations on response to ponatinib and end of treatment mutation analysis in patients with chronic myeloid leukemia.. *Journal of Clinical Oncology*, **2013**, 31, 7001-7001	2.2	2
81	EPIC: A phase III trial of ponatinib (PON) versus imatinib (IM) in patients (pts) with newly diagnosed CP-CML.. *Journal of Clinical Oncology*, **2014**, 32, 7023-7023	2.2	2
80	Efficacy and safety of ponatinib in heavily pretreated leukemia patients in the PACE trial: 3-year results.. *Journal of Clinical Oncology*, **2015**, 33, e18052-e18052	2.2	2
79	Randomized, Open-Label, Multicenter, Phase 2 Study of Asciminib (ABL001) As an Add-on to Imatinib Versus Continued Imatinib Versus Switch to Nilotinib in Patients with Chronic Myeloid Leukemia in Chronic Phase Who Have Not Achieved a Deep Molecular Response with Frontline Imatinib. *Blood*, **2019**, 134, 5910-5910	2.2	2
78	ATP Dependent Efflux Transporters ABCB1 and ABCG2 Are Unlikely to Impact the Efficacy, or Mediate Resistance to the Tyrosine Kinase Inhibitor, Ponatinib. *Blood*, **2011**, 118, 2745-2745	2.2	2
77	Management of Pregnancy in Women With Chronic Myeloid Leukemia. *Journal of Clinical Oncology*, **2018**, 36, 2657-2658	2.2	2
76	What's NEXT for CML-NGS mutation screening. *Blood*, **2020**, 135, 515-516	2.2	1
75	Discontinuation of Therapy and Treatment-Free Remission in CML **2016**, 183-193		1
74	Early Management of CML. *Current Hematologic Malignancy Reports*, **2019**, 14, 480-491	4.4	1
73	Is drug treatment superior to allografting as first-line therapy in chronic myeloid leukemia?. *Nature Clinical Practice Oncology*, **2008**, 5, 14-5		1
72	Next Generation Genomic Analyses in T-ALL Patients Identify Recurrent and Novel Genomic Abnormalities. *Blood*, **2020**, 136, 13-14	2.2	1
71	Pre-Imatinib Factors Can Be Used To Define the Risk of BCR-ABL Mutations for Patients with CML in Chronic Phase and Identify a Minority Who Should Have Regular Mutation Screening.. *Blood*, **2005**, 106, 1079-1079	2.2	1
70	Lymphoid Foci in Bone Marrow of Patients with Chronic Myeloid Leukaemia Treated with Imatinib.. *Blood*, **2005**, 106, 2008-2008	2.2	1
69	Production of GM-CSF by CML Cells Can Modulate the Anti-Proliferative and Pro-Apoptotic Effects of Imatinib on CML CD34+ Cells.. *Blood*, **2005**, 106, 2865-2865	2.2	1
68	The Expression of shp-1 and SHP-2: A Novel Powerful Predictor of Major Molecular Response (MMR) Achievement in Chronic Myeloid Leukemia Gleevec-Treated Patients Enrolled into the TOPS Clinical Trial.. *Blood*, **2008**, 112, 1106-1106	2.2	1
67	Enhancing the Functional Activity of the OCT-1 Influx Pump May Overcome the Negative Impact of Low OCT-1 Activity in Imatinib Treated CML Patients. *Blood*, **2008**, 112, 723-723	2.2	1
66	The Functional Activity of the OCT-1 Protein Is Predictive of Molecular Response and Survival in CP-CML Patients Treated with Imatinib: A 5 Year Update of the TIDEL Trial.. *Blood*, **2009**, 114, 507-507	2.2	1
65	Proton Pump Inhibitors Augment Nilotinib and Dasatinib Mediated Bcr-Abl Kinase Inhibition. *Blood*, **2010**, 116, 3991-3991	2.2	1

64	Survey of the Frontline Treatment and Management of Chronic Myeloid Leukemia (CML) in a Real-Word Setting: The 3rd Annual Update of the Worldwide Observational Registry Collecting Longitudinal Data on Management of Chronic Myeloid Leukemia Patients (The WORLD CML Registry). *Blood*, **2011**, 118, 1695-1695	2.2	1
63	Complete Molecular Response (CMR) Rate with Nilotinib in Patients (pts) with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) without CMR After ≥2 Years on Imatinib: Preliminary Results From the Randomized ENESTcmr Trial of Nilotinib 400 Mg Twice Daily (BID) Vs Imatinib. *Blood*, **2011**, 118, 696-696	2.2	1
62	Efficacy and Safety of Ponatinib According to Prior Approved Tyrosine Kinase Inhibitor (TKI) Therapy in Patients with Chronic Myeloid Leukemia in Chronic Phase (CP-CML): Results From the PACE Trial. *Blood*, **2012**, 120, 3749-3749	2.2	1
61	First-Line Treatment and Management of Chronic Myeloid Leukemia (CML) in Clinical Practice: Update of > 1800 Patients (Pts) in the WORLD CML Registry. *Blood*, **2012**, 120, 3750-3750	2.2	1
60	The Clinical Significance of Early Imatinib Induced ABCB1 Overexpression in Chronic Phase CML Patients: A TIDEL II Sub-Study. *Blood*, **2015**, 126, 348-348	2.2	1
59	A 20 Gene Expression Signature That Predicts Early Molecular Response Failure in Chronic Phase CML Patients Treated with Frontline Imatinib. *Blood*, **2015**, 126, 596-596	2.2	1
58	Switch to nilotinib versus continued imatinib in patients (pts) with chronic myeloid leukemia in chronic phase (CML-CP) with detectable BCR-ABL after 2 or more years on imatinib: ENESTcmr 12-month (mo) follow-up.. *Journal of Clinical Oncology*, **2012**, 30, 6505-6505	2.2	1
57	Integrating genetic and epigenetic factors in chronic myeloid leukemia risk assessment: toward gene expression-based biomarkers. *Haematologica*, **2021**,	6.6	1
56	Clinical development of asciminib (ABL001) in chronic myeloid leukemia (CML): A randomized phase 3 study vs. bosutinib.. *Journal of Clinical Oncology*, **2018**, 36, TPS7081-TPS7081	2.2	1
55	Management of Patients with Chronic Myeloid Leukemia **2014**, 35-51		1
54	Achieving the Deep Molecular Response Levels Required for an Imatinib Discontinuation Trial Is Strongly Associated with the BCR-ABL Level at the First Qualifying Timepoint. *Blood*, **2014**, 124, 4561-4561	2.2	1
53	A Low Concentration of ABL001 Potentiates In Vitro TKI-Induced Bcr-Abl Kinase Inhibition in CML Cells. *Blood*, **2016**, 128, 1121-1121	2.2	1
52	Impact of early landmark responses with ponatinib on 4-yr outcomes in CP-CML patients (pts) in PACE, a pivotal phase II trial.. *Journal of Clinical Oncology*, **2017**, 35, 7050-7050	2.2	1
51	DNA-Based Monitoring of Minimal Residual Disease(MRD) in Chronic Myeloid Leukemia(CML).. *Blood*, **2008**, 112, 1111-1111	2.2	1
50	Impact of early molecular response to nilotinib (NIL) or imatinib (IM) on the long-term outcomes of newly diagnosed patients (pts) with chronic myeloid leukemia in chronic phase (CML-CP): Landmark analysis of 4-year (y) data from ENESTnd.. *Journal of Clinical Oncology*, **2013**, 31, 7054-7054	2.2	1
49	High-risk B-cell acute lymphoblastic leukaemia presenting with hypereosinophilia and acquiring a novel PAX5 fusion on relapse. *British Journal of Haematology*, **2020**, 191, 301-304	4.5	1
48	Counterpoint: There is a best duration of deep molecular response for treatment-free remission, but it is patient-specific, and that is the challenge. *British Journal of Haematology*, **2021**, 192, 24-27	4.5	1
47	Treatment-Free Remission After Second-Line Nilotinib Treatment. *Annals of Internal Medicine*, **2018**, 169, 510	8	1

46	Chronic Myeloid Leukaemia **2015**, 419-437		0
45	COVID-19 in Patients with Chronic Myeloid Leukemia: Poor Outcomes for Patients with Comorbidities, Older Age, Advanced Phase Disease, and Those from Low-Income Countries: An Update of the Candid Study. *Blood*, **2021**, 138, 634-634	2.2	0
44	Trial in Progress: A Multicenter, Open Label, Randomized, Phase III Study of Asciminib (80 mg Once Daily) Vs Investigator-Selected TKI in Newly Diagnosed Adult Patients with Chronic Myeloid Leukemia in Chronic Phase. *Blood*, **2021**, 138, 1478-1478	2.2	0
43	RNA Splicing Defects in Cancer-Linked Genes Indicate Mutation or Focal Gene Deletion and Are Associated with TKI Resistance in CML. *Blood*, **2019**, 134, 662-662	2.2	0
42	Epigenetic modifier gene mutations in chronic myeloid leukemia (CML) at diagnosis are associated with risk of relapse upon treatment discontinuation.. *Blood Cancer Journal*, **2022**, 12, 69	7	0
41	Response to NOverexpression of ABCB1 as prediction marker for CML: How close we are to translation into clinics?N*Leukemia*, **2017**, 31, 769-770	10.7	
40	Treatment Free Remission for Chronic Myeloid Leukemia in 2017. *Clinical Lymphoma, Myeloma and Leukemia*, **2017**, 17, S102-S104	2	
39	Challenges of Treatment: Tyrosine Kinase Inhibitor-Resistant Chronic Myeloid Leukemia **2014**, 53-65		
38	Response: Reliability of PCR for BCR-ABL transcripts. *Blood*, **2007**, 109, 2263-2264	2.2	
37	DNA-Based Measurement of BCR-ABL in Chronic Myeloid Leukemia (CML).. *Blood*, **2007**, 110, 2946-2946	2.2	
36	IKZF1 (Ikaros) Deletions Are a Hallmark of BCR-ABL1 Positive Acute Lymphoblastic Leukemia.. *Blood*, **2007**, 110, 721-721	2.2	
35	An MMR Control RNA for Reliable Monitoring of BCR-ABL Transcripts in Treated CML Patients.. *Blood*, **2007**, 110, 2939-2939	2.2	
34	High Recombination Activating Gene (RAG) Expression and RAG Mediated Recombination Is Associated with Oncogenic Rearrangement Observed with Tyrosine Kinase Inhibitor Resistant CML. *Blood*, **2018**, 132, 3001-3001	2.2	
33	Accumulation of JAK Activation-Loop Phosphorylation Promotes Type I JAK Inhibitor Withdrawal Syndrome in Myelofibrosis. *Blood*, **2018**, 132, 1787-1787	2.2	
32	The IC50 Assay Is Predictive of Molecular Response, and Indicative of Optimal Dose in De-Novo CML Patients.. *Blood*, **2008**, 112, 1109-1109	2.2	
31	Mathematical Simulation of BCR-ABL Real Time Quantitative Polymerase Chain Reaction (RQ-PCR) for Chronic Myeloid Leukemia (CML) Response Monitoring Provides Insight on the Basis of International Standardization.. *Blood*, **2008**, 112, 2124-2124	2.2	
30	Steady-State Imatinib Trough Levels as Well as Dose Interruptions Are Associated with Clinical Response (CCyR and MMR) and Adverse Events (AEs) in Patients with Chronic Myeloid Leukemia (CML) Receiving IM as Frontline Therapy.. *Blood*, **2009**, 114, 2213-2213	2.2	
29	A Worldwide Observational Registry Collecting Longitudinal Data On the Management of CML Patients (The WORLD CML Registry) - Summary of the First 1001 Patients.. *Blood*, **2009**, 114, 4267-4267	2.2	

28	Association Between Imatinib (IM) Transporters and Metabolizing Enzymes Genotype and Response in Newly Diagnosed Chronic Myeloid Leukemia (CML) Patients (Pts) Is Influenced by Ethnicity.. *Blood*, **2009**, 114, 3283-3283	2.2
27	Analysis of Molecular Data and the Emergence of Mutations for Chronic-Phase Chronic Myelogenous Leukemia (CML-CP) Patients Treated with Dasatinib After Imatinib Failure.. *Blood*, **2009**, 114, 3282-3282	2.2
26	Early Switching From Imatinib to Nilotinib In CML Patients Failing to Achieve Early Molecular Targets May Not Be An Effective Approach In Patients with Very Low OCT-1 Activity: A TIDEL II Sub-Study. *Blood*, **2010**, 116, 356-356	2.2
25	Imatinib PK: Observations From the TIDEL II Study. *Blood*, **2010**, 116, 2288-2288	2.2
24	Specific Drug Transporter Genotypes Are Significantly Associated with Increased Rates of Major and Complete Molecular Responses In Newly Diagnosed Chronic Myeloid Leukemia Patients Treated with Imatinib A TOPS Correlative Substudy. *Blood*, **2010**, 116, 670-670	2.2
23	Detection of Low Level Nilotinib or Dasatinib Resistant BCR-ABL Mutations by Mass Spectrometry In CML Patients Who Fail Imatinib Is Highly Predictive of Their Subsequent Clonal Expansion When Treated with the Drug for Which Their Mutation Confers Resistance. *Blood*, **2010**, 116, 891-891	2.2
22	Towards DNA-Based Monitoring of Therapy In Chronic Myeloid Leukemia. *Blood*, **2010**, 116, 2284-2284	2.2
21	Modelling of TKI Resistance In CML Cell Lines: Kinase Domain Mutations Usually Arise In the Setting of BCR-ABL Overexpression.. *Blood*, **2010**, 116, 3383-3383	2.2
20	Mutation Analysis of BCR-ABL Tyrosine Kinase Domain In New Chronic Phase-Chronic Myeloid Leukemia Patients with Suboptimal Response or Treatment Failure From Imatinib Treatment.. *Blood*, **2010**, 116, 3441-3441	2.2
19	Therapy of Advanced-Stage and Resistant Chronic Myeloid Leukemia281-295	
18	Targeting Rac2 - Mitochondrial Respiratory Chain Complex III Signaling to Prevent Genomic Instability in Leukemia Stem and Progenitor Cells. *Blood*, **2011**, 118, 2736-2736	2.2
17	The Strategy of Early Nilotinib Switch Based on Failure to Achieve Optimal Molecular Targets on Imatinib May Not Overcome the Negative Impact of a Low OCT-1 Activity in De-Novo CP-CML Patients. *Blood*, **2011**, 118, 1690-1690	2.2
16	Non-Steroidal Anti-Inflammatory Drugs and Imatinib; Drug Interactions That May Impact Efficacy,. *Blood*, **2011**, 118, 3501-3501	2.2
15	Multiple Low Level Mutations Identifies Imatinib Resistant CML Patients At Risk of Poor Response to Second-Line Inhibitor Therapy, Irrespective of the Resistance Profile of the Mutations. *Blood*, **2011**, 118, 111-111	2.2
14	The patient's BCR-ABL1 Kinase Domain Mutation History Is Important for Decisions Regarding Tyrosine Kinase Inhibitor Therapy. *Blood*, **2012**, 120, 1692-1692	2.2
13	Switching patients (pts) with chronic myeloid leukemia in chronic phase (CML-CP) with residual disease on long-term imatinib (IM) to nilotinib (NIL): ENESTcmr 24-mo follow-up.. *Journal of Clinical Oncology*, **2013**, 31, 7053-7053	2.2
12	EPIC: A phase III randomized, open-label study of ponatinib versus imatinib in adult patients with newly diagnosed chronic myeloid leukemia in chronic phase.. *Journal of Clinical Oncology*, **2013**, 31, TPS7129-TPS7129	2.2
11	MicroRNA Dysregulation in Newly Diagnosed Chronic Myeloid Leukaemia Patients. *Blood*, **2013**, 122, 4985-4985	2.2

10	The Depth Of In Vivo Kinase Inhibition Achieved Over The First Month Of Nilotinib Therapy Predicts For Subsequent Molecular Response, and Is Closely Related To Nilotinib Plasma Levels. *Blood*, **2013**, 122, 256-256	2.2
9	Role Of Peroxisome Proliferator-Activated Receptor Gamma (PPAR) and Its Ligands In The Regulation Of Functional OCT-1 Activity In CML Cells. *Blood*, **2013**, 122, 1470-1470	2.2
8	STAT5 Is a Critical Component Of The Time-Dependent Sensitivity Of CML Cells To TKI Treatment In a Bcr-Abl-Dependent, But JAK2-Independent Manner. *Blood*, **2013**, 122, 2705-2705	2.2
7	PCR-Mediated Recombination Can Lead To Artificial Chimera Formation, Which May Pose As BCR-ABL1 Compound Mutations. *Blood*, **2013**, 122, 4014-4014	2.2
6	Increasing Expression Of The Efflux Transporter ABCB1 May Predispose CML Cells To Overt TKI Resistance. *Blood*, **2013**, 122, 5157-5157	2.2
5	Additional BCR-ABL1 Mutations Identified By Sensitive Mass Spectrometry In Chronic Phase CML Patients With T315I Treated With Ponatinib Are Associated With Relatively Inferior Responses and Outcome. *Blood*, **2013**, 122, 651-651	2.2
4	modeling of TKI resistance in the high-risk B-cell acute lymphoblastic leukemia fusion gene - implications for targeted therapy. *Leukemia and Lymphoma*, **2021**, 62, 1157-1166	1.9
3	Treatment-Free Remission in CML: Selecting the Best Candidates. *Clinical Lymphoma, Myeloma and Leukemia*, **2018**, 18, S3-S5	2
2	Response-Related Predictors of Survival and of Treatment-Free Remission in CML. *Hematologic Malignancies*, **2021**, 245-264	0
1	Highly sensitive droplet digital polymerase chain reaction for BCR :: ABL1 messenger RNA identifies patients with chronic myeloid leukaemia with a low probability of achieving treatment-free remission. *British Journal of Haematology*,	4.5